Today is shaping up negative for ProQR Therapeutics N.V.( NASDAQ:PRQR ) shareholders, with the analysts delivering a substantial negative revision to this year's forecasts. Revenue estimates were cut sharply as the analysts signalled a weaker outlook - perhaps a sign that investors should temper their expectations as well.
After the downgrade, the consensus from ProQR Therapeutics' four analysts is for revenues of €15m in 2026, which would reflect a measurable 7.2% decline in sales compared to the last year of performance. Per-share losses are expected to explode, reaching €0.50 per share. Yet before this consensus update, the analysts had been forecasting revenues of €19m and losses of €0.51 per share in 2026. So there's definitely been a change in sentiment in this update, with the analysts administering a substantial haircut to this year's revenue estimates, while at the same time holding losses per share steady.
See our latest analysis for ProQR Therapeutics
Taking a look at the bigger picture now, one of the ways we can understand these forecasts is to see how they compare to both past performance and industry growth estimates. We would highlight that sales are expected to reverse, with a forecast 9.4% annualised revenue decline to the end of 2026. That is a notable change from historical growth of 49% over the last five years. Compare this with our data, which suggests that other companies in the same industry are, in aggregate, expected to see their revenue grow 22% per year. It's pretty clear that ProQR Therapeutics' revenues are expected to perform substantially worse than the wider industry.
The Bottom Line
Unfortunately analysts also downgraded their revenue estimates, and industry data suggests that ProQR Therapeutics' revenues are expected to grow slower than the wider market. Given the stark change in sentiment, we'd understand if investors became more cautious on ProQR Therapeutics after today.
With that said, the long-term trajectory of the company's earnings is a lot more important than next year. At Simply Wall St, we have a full range of analyst estimates for ProQR Therapeutics going out to 2028, and you can see them free on our platform here.
Another way to search for interesting companies that could be reaching an inflection pointis to track whether management are buying or selling, with our free list of growing companies backed by insiders .
Have feedback on this article? Concerned about the content? Get in touch
with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature.
We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.
It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
